A Phase III Randomized, Open-Label, Multi-Center Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients in Asia Pacific with Advanced Non Small-Cell Lung Cancer (NSCLC)

A Phase III Randomized, Open-Label, Multi-Center Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients in Asia Pacific with Advanced

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20161027002

Enrollment

Registered

2016-10-27

Start date

2016-12-15

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Biologic combination,Biologic,Chemotherapy

Experimental Drug,Experimental Drug,Experimental Drug

Medi&#45

4736 + Tremelimumab,Medi&#45

4736,SOC

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -Stage IV NSCLC -Age > 18 years -No prior systemic treatment for stage IV NSCLC

Exclusion criteria

Exclusion criteria: - Other primary malignancy - Active infection - Any concurrent diseases not suitable for the study

Design outcomes

Primary

Measure	Time frame
PFS every 6 weeks Imaging,OS every 12 weeks vital status	—

Secondary

Measure	Time frame
safety every 4 weeks adverse event report	—

Countries

Thailand

Contacts

Public ContactNongluk Yimsuan

Astrazeneca

ynongluk@gmail.com02-7397400

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026